CASI Pharmaceuticals (FRA:ENM) DeferredTaxAndRevenue: €2.21 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ENM CASI Pharmaceuticals Inc FRA:ENM
29 GF Score
Price €1.54
GF Value €11.78
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals DeferredTaxAndRevenue?

CASI Pharmaceuticals FRA:ENM 29 DeferredTaxAndRevenue is €2.21 Mil as of Dec. 2025. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.78. The stock has 5 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

CASI Pharmaceuticals's current deferred tax and revenue for the quarter that ended in Dec. 2025 was €2.21 Mil.

CASI Pharmaceuticals DeferredTaxAndRevenue Related Terms

CASI Pharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals DeferredTaxAndRevenue Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.47 2.33 2.36 2.21

CASI Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.36 0.00 0.00 0.00 2.21
FRA:ENM
29GF Score
CASI Pharmaceuticals Inc FRA:ENM
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of €2.21 Mil mean?
CASI Pharmaceuticals (FRA:ENM) has a DeferredTaxAndRevenue of €2.21 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on CASI Pharmaceuticals.
Is CASI Pharmaceuticals' DeferredTaxAndRevenue too high?
CASI Pharmaceuticals' current DeferredTaxAndRevenue is €2.21 Mil. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' DeferredTaxAndRevenue compare to ITRMF and OGEN?
CASI Pharmaceuticals' DeferredTaxAndRevenue of €2.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on CASI Pharmaceuticals. CASI Pharmaceuticals's current DeferredTaxAndRevenue is €2.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current DeferredTaxAndRevenue of €2.21 Mil. The stock's GF Value™ is €11.78, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current DeferredTaxAndRevenue is €2.21 Mil. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current DeferredTaxAndRevenue is €2.21 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.78.

Key valuation signals for FRA:ENM:

  • DeferredTaxAndRevenue: €2.21 Mil
  • GF Value™: €11.78 vs. price of €1.54 (86.9% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Other Exchanges CASIF:USA
Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for FRA:ENM

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price
€11.78
GF Value